MCC
SNOA icon

Malaga Cove Capital’s Sonoma Pharmaceuticals SNOA Stock Holding History

Malaga Cove Capital’s Portfolio SNOA Stock Details SNOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-48
Closed -$45K – 158
2017
Q3 		$45K Buy
+48
New +$52K 0.03% 147

Other funds holding SNOA

BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GW
GW & Wade Wellesley, Massachusetts $3.08B AUM 18.99% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Malaga Cove Capital's SNOA Position: Q4 2017 in Review

Malaga Cove Capital sold out of Sonoma Pharmaceuticals (SNOA) in Q4 2017, closing a stake of 48 shares — an estimated $45K sold.

Malaga Cove Capital first reported a position in SNOA in Q3 2017 and held it in 1 quarter. The position peaked at $45K in Q3 2017. 18 funds tracked by Wall St. Rank hold SNOA as of Q4 2017.

  • Malaga Cove Capital reported no remaining Sonoma Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Malaga Cove Capital sold 48 Sonoma Pharmaceuticals shares in Q4 2017, an estimated $45K.
  • Malaga Cove Capital first reported a position in Sonoma Pharmaceuticals in Q3 2017 and held it in 1 quarter.
  • Malaga Cove Capital's Sonoma Pharmaceuticals position peaked at $45K in Q3 2017.
  • 18 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q4 2017.

Based on Malaga Cove Capital's 13F filing for Q4 2017, filed 31 Jan 2018.